M

MBX Biosciences Inc
NASDAQ:MBX

Watchlist Manager
MBX Biosciences Inc
NASDAQ:MBX
Watchlist
Price: 13.68 USD 16.92% Market Closed
Market Cap: 457.2m USD

Operating Margin
MBX Biosciences Inc

0%
Current
0%
Average
6.6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-81.4m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
MBX Biosciences Inc
NASDAQ:MBX
457.2m USD N/A
US
Eli Lilly and Co
NYSE:LLY
757.1B USD
40%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
406.8B USD
26%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
45%
CH
Roche Holding AG
SIX:ROG
207.8B CHF
33%
CH
Novartis AG
SIX:NOVN
179.9B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
165.5B GBP
24%
US
Merck & Co Inc
NYSE:MRK
211.3B USD
34%
IE
Endo International PLC
LSE:0Y5F
183.8B USD
11%
US
Pfizer Inc
NYSE:PFE
144.2B USD
27%

MBX Biosciences Inc
Glance View

Market Cap
457.2m USD
Industry
Pharmaceuticals

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana and currently employs 36 full-time employees. The company went IPO on 2024-09-13. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

MBX Intrinsic Value
7.84 USD
Overvaluation 43%
Intrinsic Value
Price
M
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-81.4m
/
Revenue
0
What is the Operating Margin of MBX Biosciences Inc?

Based on MBX Biosciences Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top